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Abstract To obtain information on the occurrence and
location of molecular events as well as to track target-specific
probes such as antibodies or peptides, drugs or even cells non-
invasively over time, optical imaging (OI) technologies are
increasingly applied. Although OI strongly contributes to the
advances made in preclinical research, it is so far, with the
exception of optical coherence tomography (OCT), only very
sparingly applied in clinical settings. Nevertheless, as OI
technologies evolve and improve continuously and represent
relatively inexpensive and harmful methods, their implemen-
tation as clinical tools for the assessment of children disease is
increasing. This review focuses on the current preclinical and
clinical applications as well as on the future potential of OI in
the clinical routine. Herein, we summarize the development of
different fluorescence and bioluminescence imaging techni-
ques for microscopic and macroscopic visualization of micro-
structures and biological processes. In addition, we discuss
advantages and limitations of optical probes with distinct
mechanisms of target-detection as well as of different
bioluminescent reporter systems. Particular attention has been
given to the use of near-infrared (NIR) fluorescent probes
enabling observation of molecular events in deeper tissue.
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Introduction
In recent years, various in vivo imaging technologies
have been increasingly used to monitor biological
processes and to understand the complexity of diseases.
Many of them progressively find application in clinical
procedures allowing earlier and more precise diagnosis.
Nevertheless, none of them provides comprehensive
information since each imaging technique relies on
different mechanisms for signal generation and thus has
limitations e.g., with respect to spatial resolution,
penetration depth, quantitative information and detection
sensitivity, but also to safety hazards and costs. There-
fore, each technique possesses a unique combination of
advantages and disadvantages that affects its selection for
use in a particular study. Imaging techniques such as
ultrasound (US), computed tomography (CT), and mag-
netic resonance imaging (MRI) are used to visualize
morphological properties of tissue, whereas techniques
such as positron emission tomography (PET), single-
photon emission computed tomography (SPECT) and
optical imaging (OI) with fluorescence or bioluminescence as
sources of contrast allow information to be obtained on the
location of molecular events or to follow-up distribution of
applied probes in living organisms [1]. To take advantage of
the strengths of different imaging devices, multimodal-
imaging strategies demonstrate attractive tools for preclinical
and human applications. In this review, key characteristics
and technical progress of OI as well as the current use and
potential impact of OI methods in preclinical research and in
clinical management of children are discussed.
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Fluorescence imaging is based on the detection of photons,
emitted by a substance that has absorbed light or other
electromagnetic radiation of a different wavelength. Fluores-
cence occurs when an orbital electron of a molecule, atom or
nanostructure relaxes to its ground state by emitting a photon
of light after being excited to a higher quantum state. Usually,
emitted light has a longer wavelength, and therefore a lower
energy, than the absorbed radiation.
The majority of OI systems are based on planar
measurements of fluorescence typically overlaid with
photographic images of the surface of the scanned object.
Those devices usually consist of an excitation source such
as a multispectral light source or a laser of appropriate
filters and a camera. As the excitation source and the
detector can be placed either on the same side or on
opposite sides of the scanned object, planar imaging can be
performed in an epi-illumination modus, known as fluores-
cence reflectance imaging (FRI), in which the returning
fluorescence response is measured and, less expanded,
transillumination imaging in which the light shining
through the object is collected [2]. Although not as widely
used, transillumination attains important benefits over
epifluorescence imaging such as improved depth sensitivity
and contrast, as it carries information from the entire
volume of the sample in comparison to reflectance
measurements that are surface-weighted [3].
An innovation in fluorescence imaging was the implemen-
tation of time-domain imaging that allows calculation of
fluorescence lifetime, a parameter that characterizes a fluo-
rescent probe by describing the average amount of time a
fluorophore spends in its excited state before returning to the
ground state. In this technique a pulsed laser diode is used as
an excitation source. The first photon response is measured
time-resolved with a photomultiplier tube after each single
excitation pulse and used to calculate the fluorescence
lifetime. As lifetime is a specific characteristic of particular
fluorescent probes, the determination of lifetime values
permits the identification of specific, probe-derived signals
and their separation from unspecific background fluorescence
(Fig. 1) or the discrimination of various fluorophores with
distinct fluorescence decay rates [4, 5].
In vivo fluorescence intensity measurements strongly
depend not only on the probe’s spectroscopic properties
and/or its concentration within the tissue but also on
parameters, such as depth of the fluorescence source within
the tissue or on the density and homogeneity of the tissue
itself. Therefore, traditional planar imaging of the fluores-
cence response projected on the surface of living objects
can offer only semi-quantitative data. In contrast, recent
developments in tomographic fluorescence imaging includ-
ing fluorescence-mediated tomography (FMT), optical
projection tomography (OPT) and diffuse optical tomogra-
phy (DOT) provide 3-D information about the fluorescence
distribution, based on accurate theoretical models of photon
propagation including absorption and scattering of both
excitation and emission light in tissues. The resulting
tomographic fluorescence maps reconstructed after mathe-
matical processing allow relatively accurate and true
quantification of the data independent of the depth of the
fluorescence source and have been successfully applied in
preclinical models e.g., to monitor cancerous tissue [6, 7],
to calculate vascular volume fractions [8] and to visualize
and quantify pulmonary inflammation in vivo [9]. Although
novel approaches for improved quality of 3-D fluorescence
imaging, such as DOT-guided FMT [10] are continuously
evolving, the impact of heterogeneity of living objects and
tissue optical properties on the mathematical models of
image reconstruction still requires further modification.
In order to image down to subcellular resolution, different
microscopic techniques have adapted to in vivo fluorescence
Fig. 1 Fluorescence lifetime imaging in vivo. a NIRF raw scan data
of a living mouse with a pancreatic tumour obtained 24 h after
application of an anti-matriptase antibody shows signals with a probe-
specific lifetime of 1.7 ns detectable over the tumour area (L1), as well
as nonspecific signals (3.5 ns) over the stomach area (L2). b A
representative photon time-of-flight histogram; each line corresponds
to a single point on the raw scan. c Lifetime map displays the
distribution of the different fluorescence species. d After gating the
lifetime to 1.5–2.0 ns only specific, probe-derived fluorescence over
the tumour is detectable
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confocalmicroscopy.Inaddition,optoacoustic(photoacoustic)
techniques evolved for the microscopic imaging of intact
tissue. In comparison to whole-body imaging systems,
microscopic devices operate with small fields of view and
therefore allow imaging only in selected parts of tissues.
Furthermore,becauseoftheverylimitedpenetrationdepth,the
microscopic imaging of deeper tissues requires invasive
procedures, e.g., the use of implantable windows, endoscopes
or miniaturized fibre-based catheters. Such micro(endo)scopic
techniques allow functional information on dynamic processes
within tissues and organ systems to be obtained that are
maintained in their natural state and provide “optical biopsies”
of living tissues by avoiding the risks, costs and time delay
involved in tissue resection.
Confocal (intravital) microscopy is relatively inexpen-
sive and user-friendly. This method relies on a laser source
that focuses on a single spot in the sample and the light
emitted from this focal point is imaged through a pinhole
onto a detector. Here, phototoxicity can be a limiting factor
especially during long scanning times. As the optical
penetration of confocal microscopy into tissues is limited
to 200–500 μm, its clinical application is restricted to
examinations of superficial structures such as visualization
of melanocytic skin tumours [11]. Two- or multiphoton
microscopy imaging is based on the simultaneous absorption
of two or more photons under high light irridance. Due to its
capacity for deep penetration of up to 800 μm, its efficient
light detection and the potential to image tissue for hours in
high spatial resolution, this technique is increasingly used as
an efficient and less phototoxic imaging approach to
investigate biological processes in deep and vital tissues
within their intact environment [12].
Optical coherence tomography (OCT), that uses broad-
band NIR light sources with considerable penetration of
about 2–3 mm into tissue, is one of the most promising
techniques for biomedical tissue imaging. In clinical
practice OCT is applied mainly to provide information on
easily accessible tissues such as skin, gastrointestinal and
retinal pathology in situ and in real time. It provides optical
biopsies with resolutions approaching those of excisional
biopsy and histopathology based on the detection of
inhomogeneities [13]. Tissue microstructure is revealed by
differentiating between scattered and transmitted, or
reflected photons [14]. As it enables measurement of tissue
pathology with resolution of several micrometers (1–
15 μm) OCT perfectly fills the gap between microscopic
and whole-body imaging techniques.
Based on the measurement of optical absorption in
tissues photoacoustic microscopy that detects absorbed
photons ultrasonically through the photoacoustic effect is
also an emerging tool for in vivo imaging [15]. This
method provides multiwavelength imaging of optical
absorption and permits better spatial resolution than pure
optical imaging since the imaging depth is beyond ~1 mm
[16].
Endogenous fluorescent labels/genetic reporters
The revolution in the development of fluorescence
imaging was the identification of the first fluorescent
protein, green fluorescent protein (GFP) from jellyfish,
purified and characterized in the early 1970s [17].
However, it took almost 20 years until the whole GFP
was cloned and sequenced [18]. Today fluorescent proteins
exist in many colours that span the visible spectrum from
deep blue to deep red. The utility of these genetically
encoded probes for in vivo fluorescence labelling has been
demonstrated in a variety of different cellular systems and
transgenic organisms. For example, interactions between
host and tumour environment have been studied in GFP-
expressing transgenic mice transplanted with red fluores-
cent protein (RFP)-expressing cancer cells. This approach
allowed the distinction between cancer and host cells
including host blood vessels, lymphocytes, tumour-
associated fibroblasts, macrophages, etc. and was shown
to be a powerful tool to study the efficacy of drugs on each
type of cell [19].
When selecting among the many colour variants avail-
able for in vivo imaging, it is important to consider
fluorescent proteins that are very bright, most photostable
and those requiring minimal exposure to excitation to
maintain cell viability [20–22]. Fluorophores absorbing and
emitting in the NIR wavelength region between 650 nm and
900 nm are particularly valuable for in vivo imaging, since
this light spectrum not only benefits from less autofluor-
escence but is also only poorly absorbed by haemoglobin,
water and lipids, allowing up to 2-cm tissue penetration
[23]. Accordingly, endogenous gene reporters for whole-
body near-infrared fluorescence (NIRF) imaging in preclin-
ical studies have been expressed in mammalian cells such
as infrared-fluorescent proteins (IFPs), engineered from a
bacterial phytochrome [24] or the bright far-red fluorescent
protein Katushka and mKate, the monomeric form of
Kathushka [25]. Nevertheless, the clinical use of endoge-
nous fluorescent labels has its limitations due to the need
for cell-engineering and to the lack of any information on
its long-term side effects.
Exogenous fluorescent probes
The majority of the in vivo NIRF imaging studies involve
application of fluorescent probes that usually target specific
markers or molecular events in model organisms. Prereq-
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detection limit and dynamic range of the method. Such
fluorophores should have NIR absorption- and emission-
maxima, a high molar absorption coefficient at the
excitation wavelength, high fluorescence quantum yield
and sufficient thermal and photochemical stability [21, 22].
Moreover, suitable fluorescent dyes have to be soluble and
stable in buffers and body fluids and the resulting probe
should reveal maximal targeting efficiency by reduced
nonspecific binding and low toxicity [22]. The ability to
employ simultaneously different fluorescent probes in
combination with multiple imaging channels and thereby
facilitating the visualization of more than one target and
various biological processes in one animal is one functional
benefit of fluorescence over the majority of other in vivo
imaging modalities [26].
There are relatively few classes of NIRF dyes available
for in vivo imaging including organic dyes such as
phthalocyanines, cyanine dyes and squaraine dyes. Most
of the currently used NIR fluorochromes are cyanine dyes
containing two heterocyclic rings linked by a polymethine
bridge e.g., Cy-, DY-, IR-dyes, or AlexaFluor-dyes, cypate
and indocyanine green (ICG) [27]. Despite ongoing efforts
in the design of novel fluorescent probes up to now only
one fluorescent dye, ICG, has been approved by the Food
and Drug Administration-USA (FDA) for use in patients
e.g., for the intraoperative assessment of reconstructed
vessels in living-donor liver transplantations [28]o ri n
ophthalmic angiography [29].
Although organic fluorophores represent the major group
of the fluorescent probes for in vivo application, they
usually suffer from low fluorescence quantum yields and
limited sensitivity and photostability as well as from
agglomeration and susceptibility to environmental changes
in blood or tissues. Moreover, many of them possess a
certain level of toxicity that hampers their in vivo
application. One of the solutions is enclosure of fluorescent
dyes in nanomaterials, such as polymeric nanoparticles
(NPs), which can be fabricated from a multitude of
materials in a variety of compositions and doped with
different fluorophores. This has the advantage of protecting
the potentially toxic fluorophores from the environment and
offers improved fluorophore stability due to reduced
interactions with the environment, e.g., solvent molecules,
chemically reactive species or quenching agents [30]. The
main advantage of using NPs is their large surface areas
allowing easy modification with a wide range of imaging
moieties including several surface modifications for multi-
modal detection and/or drug delivery [31], but also surface
attachment of target-specific bioligands or polymeric com-
pounds such as polyethylene glycol (PEG). In particular,
PEGylation is of particular interest as it strongly influences
the pharmacokinetics of NPs by reducing clearance by the
reticuloendothelial system and increasing plasma half-lives
of the NPs but also their stability and water solubility while
reducing their immunogenicity [32, 33].
Nevertheless, many presently available NP-formulations
comprise potentially toxic elements. In spite of growing
efforts to reduce side effects, such as using biodegradable
coatings, the biodistribution, behaviour and risks of using
NPs in living organism still have to be studied [34].
Luminescent semiconducting nanocrystals, quantum
dots (QDs), which can readily be conjugated to targeting
molecules (e.g., antibodies), are also increasingly used as
fluorescent labels for in vivo imaging. Unlike organic dyes,
QDs can be excited over a broad wavelength and their
optical properties are controlled by the constituent material,
particle size and dispersity, shape and surface chemistry.
The use of QDs for in vivo imaging is also hampered by the
contradictory reports on their toxicity [22].
Three major classes of fluorescent reporters can be
distinguished, based on their mechanisms of target-
detection: (1) nontargeted contrast agents that nonspecifi-
cally accumulate in certain tissues, (2) target-specific
fluorescent labels that are directed against molecular and/
or disease-specific markers and (3) responsive/activatable
“smart” probes for the detection of molecular events such
as enzymatic activity or pH sensing.
Nontargeted fluorescent probes
Nontargeted (passive) contrast agents deliver fluorescent
probes to a certain tissue without specifically binding to
cellular targets. There are two major targets for passive
imaging: blood vessels and tumour tissue. Accumulation of
non-targeted probes at the tumour sites is achieved by
pathologically enhanced endocytic activity, hyperpermeable
and leaky vasculature and lack, or abnormal lymphatic
drainage, attributes, which can be summarized as the
enhanced permeability and retention (EPR) effect. As the
abolished integrity of the endothelial barrier inthe vasculature
is an integral part of different diseases, nontargeted contrast
agents have been used to visualize cancer but also other
pathological sites such as inflammation, rheumatoid arthritis
or infarction. Since a sufficient blood circulation time is
essentialforthe successfuldeliveryofprobes,thelongevityof
contrast agents in the blood stream is necessary to permit
accumulation within the targeted tissue.
Several nonspecific contrast agents are commercially
available, such as ICG systematically used for ophthalmic
angiography in clinical settings [35, 36] and to imagine
blood flow using video angiography during cerebral
surgery in clinical trials [37]. An NIRF blood-pool contrast
agent AngioSense, consisting of PEGylated graft copolymers
andindocyanine-typefluorophore,canbeusedformonitoring
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leakage in tumours, as well as for visualization of oedema
and inflammation [8]. Also fluorophore-doped NPs, such as
viral NPs [38], liposomes [39]a n dQ D s[ 40] have been used
as tools for passive vascular imaging in preclinical settings.
Here, size, composition and surface hydrophilicity of NPs,
can influence their blood circulation time.
Targeting probes
The majority of imaging probes consist of fluorophores or
fluorescent nanomaterials attached to ligands, e.g., anti-
bodies, antibody fragments or peptides targeting a tissue- or
disease-specific molecule/-s. In recent years reams of
monoclonal antibodies conjugated to fluorescent labels
have been used for in vivo imaging. One example is
trastuzumab (Herceptin), a well-characterized and clinically
applied humanized anti-HER2/neu monoclonal antibody,
fused to Cy5 (Fig. 3)[ 41] Cy5.5 [42] or ICG [43] for
detection of HER2/neu-overexpressing tumours in mice.
Our own work demonstrated the use of different Cy5.5
labelled monoclonal antibodies in orthotopic mouse tumour
models, for example, to assess the expression of the
tumour-associated protease, matriptase in pancreatic
tumours [4] (Fig. 1) or to preclinically evaluate antibodies
[44, 45] for their use in anti-tumour therapies.
Emerging progression in recombinant DNA technologies
raced the optimization of the traditional monoclonal anti-
bodies used for imaging and treatment by new structural
designs including production of chimeric and humanized
antibodies or recombinant antibodyfragments [46]. However,
several aspects have to be considered when applying
antibodies, antibody fragments or peptides for in vivo
imaging. First of all, the biodistribution and pharmacokinet-
ics of ligands is strongly influenced by their size. Compa-
rably large whole antibodies are slowly cleared from the
blood circulation and only slowly penetrate into tissues,
which can result in a high background and poor tissue-to-
background contrast [47]. Molecules smaller than antibodies
such as antibody fragments or peptides, can be advantageous
for in vivo targeting because of their rapid blood clearance
resulting in better signal-to-background ratios. If clearance is
too fast, however, small ligands will not have sufficient time
to penetrate target tissues before they are removed from the
blood pool. In addition, in contrast to whole monoclonal
antibodies, which usually arise from mice, engineered
antibody fragments are expected to be only minimally
immunogenic in human applications. Also, the affinity of a
particular ligand for its antigen can influence its diffusion
into the target tissue. High affinity increases the amount of
ligand in the targeted tissue only up to a certain threshold,
above which tumour penetration is reduced or even inhibited
[48]. This occurs due to the (too) strong interaction and
usually irreversible association of the ligand with its antigen
molecules present in close proximity to the blood vessels,
thereby avoiding further diffusion of the ligand into the
tissue. This so-called binding site barrier effect was
postulated by Weinstein in early 1990s and is especially
true for large and poorly vascularized tumours [48, 49].
Furthermore, other factors such as systemic clearance of
probes, density of cells in the desired tissue, or high
interstitial pressure e.g., within tumours have to be consid-
ered when using antibodies, antibody fragments or peptides
for tissue-targeting [50]. Intermediate-size molecules with
reduced blood circulation times, however long enough to
Fig. 2 Visualization of tumour vascularization using a nontargeted
blood pool contrast agent. a NIRF image acquired 1 h after
intravenous injection of AngioSense
680 into a mouse bearing a
glioblastoma xenograft. Strong fluorescence is measured over the
tumour (T) indicating high vascularization. Two large tumour-
supplying vessels show strong fluorescence (arrows). b High-
resolution anatomical scan, performed by flat panel volume CT
(fpVCT), 90 s after intravenous application of 150 μl iodine-
containing blood pool agent confirmed the localization of the same
two large blood vessels (arrows) detected in (a), and also shows
smaller tumour vessels (pink). c Macroscopic image of the same
mouse confirms the presence of the two large vessels (arrows)
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probes. For example, anti-HER2/neu affibody molecules
(small high affinity proteins of few kDa) labelled with
AlexaFluor dyes allowed visualizing HER2-expressing
tumours without interfering with the therapeutic efficacy of
Herceptin [51]. Further, NIRF-labelled ligands such as
vascular endothelial growth factor (VEGF) [52]o rf o l i c
acid, an agonist binding to the folate receptor [53], have been
used to monitor tumour angiogenesis and arthritis in vivo,
respectively. A peptide-dye conjugate consisting of cyclic
arginine-glycine-aspartic acid pentapeptide attached to Cy5.5
(RGD-Cy5.5) was applied to determine integrin expression
in vivo with high specificity and long-lasting tumour
accumulation [54]. Furthermore, fluorophore-labelled toxins,
such as Cy5.5-labelled chlorotoxin, a small peptide from the
venom of the deathstalker scorpion Leiurus quinquestriatus,
have been applied as optical probes for NIRF imaging.
Cy5.5-labeled chlorotoxin enabled delineation of malignant
glioma, medulloblastoma, prostate cancer, intestinal cancer
and sarcoma from adjacent non-neoplastic tissue in mouse
models and to detect metastatic cancer foci as small as a few
hundred cells in lymph channels [55].
Activatable probes
A group of “smart” activatable or responsive probes
evolved to detect and quantify target-specific enzymes,
molecular processes as well as changes in oxygen or pH
levels in living organisms over time. Such probes usually
display “switch-on” or increase in the fluorescence emis-
sion or shifts in the absorption and/or emission spectra
upon specific processes, such as cleavage of the probe or
changes in the probe-environment.
Protease-sensing
First concepts of protease-sensing probes, polymer-based
optically quenched activatable probes for tumour imaging
were introduced by Weissleder’sg r o u p[ 56]. They consist of
fluorochromes quenched by their high density, grafted to an
enzymatically cleavable polymer backbone that functions in
vivo as a long-circulating delivery carrier. NIRF signals are
generated as a result of lysosomal cysteine/serine protease
activity in cells after probe internalization [56]. Sequentially,
activatable probes specific for certain proteases such as
cathepsin-D [57] and -K [58], caspase 1 [59], matrix
metalloproteinases (MMPs) [60] or urokinase-type plasmin-
ogen activator (uPA) [61], have been developed. They are all
based on protease-specific peptide substrates introduced
between the polymer backbone and quenched fluorophore
molecules. Further constructs are caspase-sensing NIRF NPs
for apoptosis imaging. They consist of a cleavage peptide
(DEVD) and Cy5.5 both attached to a deoxycholic acid
(DOCA)polymerbackbonethatiscleavedbycaspase-3and-7
[62].
PEG or other polymers usually conjugated to activatable
probes efficiently increase the probe stability and blood
circulation time, although withsome disadvantages. The large
molecular size of the polymer substrates (>100,000 molecular
weight) may reduce permeation into cells and many PEG
molecules might interfere with the interaction between the
peptide substrate and the target enzyme [63, 64].
A nonpolymeric small peptide selfquenched probe was
applied for the assessment of activity of matriptase, a serine
Fig. 3 Evaluation of trastuzumab and pertuzumab tumour binding by
NIRF imaging. Specific binding of (a) trastuzumab-Cy5 and (b)
pertuzumab-Cy5 antibody-conjugates to HER2/neu-expressing mam-
mary tumours in vivo. Both mice show comparable NIRF signals at the
tumour site. c and d When mice were pretreated with unlabelled
trastuzumab, no tumour staining was seen with trastuzumab-Cy5 (c,
arrow), whereas pertuzumab-Cy5 treatment showed nonaffected stain-
ing intensity indicating different binding sites for the antibodies on the
tumour site (d). The illustration is reprinted with kind permission from
Cancer Research and with courtesy of Discovery Oncology, pRED,
Roche Pharma, Penzberg from reference [41] (Figure 3)
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Due to the small molecular weight of the probe consisting
of two DY-681 molecules attached to a short peptide
containing a matriptase cleavage site, no measurable accumu-
lation of the substrate in tumour tissue was achieved.
Therefore, the activity of matriptase and its inhibition was
assessed by determination of fluorescence intensity of the
cleaved substrate accumulating in the bladder (Fig. 4)[ 4].
Dye molecules can also be attached to metal NPs such as
gold (AuNPs) in order to produce protease activatable probes
such as a MMP-cleavable AuNPs probe for tumour imaging.
Due to electronic interactions between the chromophore and
AuNPs, this binding results in very strong quenching of the
fluorescence [63].
Quenched probes for signal amplification
Another group of “smart” probes utilizes the dye quenching-
dequenching principle for signal amplification. Similar to
protease-sensors, these probes contain also a high density of
dye molecules that are attached to a ligand; here the
dequenching occurs after cell internalization of the ligand-
dye complex. One example is a nonpolymeric agent consist-
ing of two independent domains, an integrin recognizing
RGD motif as cell targeting domain and the imaging domain
composed of a Cy5 dye, a cleavable bond and a quencher.
Probe activation only occurs after RGD-integrin mediated
probe internalization followed by intracellular release of the
fluorophore into the lysosome [63]. A similar approach was
described by Ogawa et al. [43, 65], who characterized a
selfquenching probe consisting of a high number of
fluorophore molecules attached to a single antibody mole-
cule, Herceptin, that are dequenched after HER2/neu
receptor mediated internalization. This kind of smart probe
may have great potential for improving image contrast.
ß-galactosidase sensing
Bacterial ß-d-galactosidase (ß-gal) is the most widely used
reportergeneforenzymeimmunoassaysinmolecularbiology.
A variety of chromogenic and low-emitting fluorogenic
substrates have been described, but first the development of
NIRF probes, such as DDAOG or Gal-2SBPO (Fig. 5),
facilitated ß-gal activity measurements in vivo. DDAOG is a
Fig. 4 Measurement of matriptase activity using a nonpolymeric
activatable probe. Fluorescence intensity was measured over the
bladder area of a mouse (a) bearing an orthotopic pancreatic tumour
and of a tumour-free control (b) approximately 60 min after
intravenous injection of a selfquenched matriptase-activatable probe.
Enzymatic activity of matriptase in tumour-bearing mice was assessed
by increase in the fluorescence intensity in comparison to the control
Fig. 5 ß-galactosidase sensing
in vivo. a ß-gal triggered cleav-
age of DDAOG results in far red
shifts of the excitation/emission
peaks from 465/608 nm to 646/
659 nm. b The optically active
2SBPO is released after a series
of spontaneous reactions fol-
lowing the enzymatic cleavage
of the ß-d-galactopyranoside
from the gal-2SBPO by ß-gal.
The illustration (b) is used with
permission of ChemBioChem
and was taken and adapted from
Scheme 1 from reference [69]
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dichloro-9,9-dimethylacridin-2-one-7-yl)); the cleavage prod-
uct shows a far red shifted absorption and emission spectrum,
enabling its specific detection in a background of the intact
probe. Although DDAOG has been successfully applied for
imaging of ß-gal-expressing tumours and monitoring trans-
genic expression of the LacZ gene in mice, as the narrow
emission spectrum of DDAO seriously overlaps with the
absorption spectrum, this probe still needs improvements for
efficient in vivo application [66–68]. Gal-2SBPO, a ß-d-
galactopyranoside conjugate of 2SBPO (9-di-3-sulfonyl-
propylaminobenzo[a]scphenoxazonium perchloride) is a dual
fluorogenic and chromogenic substrate for ß-gal [69].
Enzymatic cleavage of the probe triggers a series of
spontaneous reactions that result in release of optically active
2SBPO. Since the substrate emits in the far-red wavelength
region, it shows promise as a reporter molecule for in vivo
imaging of ß-gal activity.
pH sensing
Changes in pH are hallmarks of numerous diseases such as
inflammation or cancer. For example, acidosis of the tumour
microenvironment that is induced by upregulated glycolysis
under hypoxic conditions is pervasive in almost all solid
tumours [70]. Based on these conditions, interest for the use
of pH-activatable probes in vivo arose. Currently, there are
only a few NIR-emitting pH-sensitive probes available; most
of the pH probes contain fluorophores that absorb and emit
in the visible region. The NIR pH sensors can be divided
into two groups. The first group is represented by self-
quenching fluorescent pH probes in which the sensors are
designed similarly to protease-sensitive selfquenchers, but
contain an acid-sensitive instead of a protease-sensitive
linker [71]. The second group comprises mainly cyanine-
or norcyanine-based dyes, with a protonatable amine group
within the chromophore, such as square-650-pH [72], or
ICG- and cypate-based sensors, H-ICG and H-cypate [73].
Whereas pH sensing on tumour cells in vitro is well-
established [74], measuring pHchanges in vivo still remains a
challenge. Here, the advantage of the activation of pH-
sensitive dyes in the acidic environment is mainly used to
increase the signal to background contrast either after
accumulation of the probe e.g. in the tumour tissue or after
receptor-mediated internalization of the dye-ligand complexes
into acidic endosomal/lysosomal compartments of the target
cell. In this way, by applying pH-activatable BODIPY-based
conjugates Urano et al. [75] were able to reach 22-fold higher
tumour-to-background ratios than using an always-on fluores-
cent probe.However,asthe BODIPY dyes absorb in therange
around 490 nm, the limited tissue penetration restricted
generation of in vivo data and allowed only ex vivo measure-
ments. Recently an in vivo enhancement of tumour contrast
was achieved by application of a novel pH-activatable NIRF
nanoprobe InNP1 [76]. Nevertheless, there is still demand for
the development of sensitive pH indicators for measuring pH
changes or to further improve tumour contrast in vivo.
Bioluminescence imaging
BLI enables a relatively robust, simple, inexpensive and
extremely sensitive detection of essential biological processes
in vivo in a variety of disease models. In contrast to
fluorescence imaging this method is based on the detection
of light produced and emitted by a living organism and it does
not necessitate any external light source for excitation.
However, BLI requires genetic labelling of cells with light
producing enzymes (the luciferases) and as mammalian cells
do not produce theluciferase-substrate responsible for the light
emission, the substrate must be delivered systematically.
Themostcommonlyusedbioluminescentreporterforsmall
animal imaging is luciferase from the firefly (Photinus
pyralis). In an oxygen-, magnesium-, and ATP-dependent
process the firefly luciferase oxidates its substrate, luciferin,
whereby light is produced with a broad emission spectrum
and peak intensity at ~560 nm [77]. Click beetle (Pyrophorus
plagiophthalamus) luciferase catalyzes green to orange (546–
593 nm) bioluminescence after oxidating luciferin [78].
Renilla (sea pansy) and Gaussia (marine copepod) luciferases
react with the substrate coelenterazine to produce blue light
(~480 nm) in an ATP-independent process [79, 80].
Moreover, lux operons from bacteria, e.g., Photorhabdus
luminescence, emit blue light that has widely been used for
BLI of bacterial infections [81]. The lux operon encodes all
proteins required for bioluminescence: luciferase, its substrate
and substrate-regenerating enzymes, enabling continuous
light production by the system without need for exogenous
substrate. Nevertheless, this autonomous light-generating
system has not been successfully transferred to mammalian
cells. Firefly luciferase is the preferred enzyme for BLI in
vivo, since it produces more light than click beetle luciferase,
has longer emission wavelength than Renilla and Gaussia
luciferases and luciferin show lower background signals but a
better biodistribution than coelenterazine. However, the avail-
ability of multiple luciferases is advantageous as it allows
different biological processest ob em o n i t o r e di np a r a l l e li n
vivo, using appropriate filter combinations and substrates [82].
Due to the abandonment of external illumination sources,
BLI provides very high detection sensitivity and low
background signals, especially when compared to fluores-
cenceimagingwheretheexternalilluminationoftissuecauses
endogenous particles of the animal to emit light. Already as
few as ~500 cells can be reliably detected in vivo at specific
anatomical sites [83]. In vivo biodistribution and pharmacol-
ogy of luciferase substrates are critical parameters in regard
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BLI. Bioluminescent signals vary with time after injection of
the substrate, e.g., luciferin distributes throughout an animal
rapidly after injection and light produced by firefly luciferase
peaks ~10–12 min after injection of luciferin and slowly
decreases afterwards. To achieve comparable results, the
time between injection of substrate and start of measurement
as well as the dose of administered substrate should be
standardized for each study [82].
Further parameters that affect the sensitivity of BLI are
the wavelength of the emitted light, the expression level of
enzymes in the target cell, the position of bioluminescent
cells in the mouse as well as the efficiency and sensitivity
of the CCD camera. A problem of planar BLI is the 10-fold
loss of photon density for each centimetre of tissue depth.
This creates surface-weighted images and lets the light
sources closer to the surface appear brighter compared with
deeper sources.
BLI can be used to study preclinically protein expression
during disease progression and in response to therapy. For
this purpose often transgenic animals are generated
expressing luciferase either ubiquitously or under the
control of a regulated promoter. As bioluminescence will
occur only when the controlling promoter is active, this
technique enables the monitoring of spatiotemporal changes
of protein expression in vivo e.g., as applied for analysis of
the heme oxygenase-1 that plays a key role in development
and where disregulation is often associated with jaundice in
neonates [84, 85]. Transgenic mice expressing luciferase
under the control of a lobe-specific promoter were used to
investigate the early onset of retinoblastoma [86]o rt o
generate luciferase expressing haematopoietic stem cells
used for the visualization of leukemogenesis after trans-
plantation in bone-marrow-depleted mice [87]. Moreover,
mice expressing luciferase fused to a region of hypoxia-
inducible factor (HIF) has been used for monitoring
hypoxic tissues (Fig. 6a). As hypoxia is a hallmark of
many paediatric diseases, such mice can be applied in
preclinical paediatric research for evaluating therapeutic
agents that stabilize HIF by monitoring hypoxia [88]. A
further possibility to introduce a gene encoding luciferase
into a living organism is transduction with viral particles
enclosing luciferase reporters that infect certain cell types to
be studied. In this context a luciferase-containing avian
retrovirus has been used in a transgenic mouse model
expressing the corresponding retrovirus receptor to study
location of haematopoietic stem cells in mice [89].
Luciferase-expressing viral vectors have further been
Fig. 6 BLI in animal models. a BLI of hypoxia. Transgenic ROSA26
ODD-Luc/+ mice ubiquitously expressing a bioluminescent reporter
consisting of firefly luciferase fused to a region of HIF that is
sufficient for oxygen-dependent degradation were breathing 21% or
8% oxygen. An approximately 5- to 10-fold increase in light emission
could be observed under hypoxic conditions. The illustration is
reprinted with kind permission of PNAS, copyright (2006) National
Academy of Sciences, U.S.A, from reference [88]. b Muscle stem cell
engraftment monitored in vivo by BLI. Increasing numbers of
luciferase-expressing myoblasts were injected into the tibialis anterior
muscles of NOD/SCID recipients and imaged with BLI 2 h after
injection. Here, the minimum number of cells detectable above control
uninjected legs was 10,000. The bioluminescence intensity increased
linearly with the number of injected cells. The illustration is reprinted
with kind permission from Macmillan Publishers Ltd: [Nature], from
reference [91], copyright (2008)
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diseases such as cystic fibrosis [90].
Moreover, transplantation of different cell types that are
modified to express luciferase is widely used to monitor
different processes such as tracking of muscle stem cells
during muscle repair (Fig. 6b)[ 91]. Transplantation of
cancerous cells is also commonly used to investigate
tumour development, growth and therapy in a variety of
animal tumour models for common childhood cancers such
as lymphoma [92]. In order to identify proteins involved in
leukaemia progression, BLI was applied in combination
with knock-down of protein expression by RNA interfer-
ence [93]. Furthermore, a bioluminescent rodent model for
studying growth and therapy of brainstem tumours (one of
the most severe neoplasms for children) has recently been
established [94]. Luciferase-expressing mouse models of
osteosarcoma, the most common primary bone tumour in
children and young adults, enabled earlier tumour detection
in comparison with tumour volume measurements as well
as detection of lung metastases and monitoring of response
to therapy in preclinical studies [95, 96].
As generation of bioluminescence in mammalian cells
requires the introduction of a DNA-encoding luciferase into
the target cell, which is a highly manipulative genetic
intervention, it is from both a medical and ethical point of
view very unlikely that BLI will ever be applied in humans.
Nevertheless, because of its high specificity and sensitivity,
BLI provides an effective and valuable preclinical tool to
investigate distinct biological processes, to explore and better
understand the biology of human diseases including distinct
processes of newborn and childhood disease or to accelerate
the development of possible therapeutic interventions.
Multimodal imaging
Since OI lacks any anatomical information, coregistration
of data from OI imaging to anatomical structures visualized
with imaging devices, such as CT, MRI, and US, is
advantageous to provide complementary information in
disease models. Combined MR and NIRF imaging include
the use of probes consisting of NIR fluorophores conjugat-
ed to iron oxide nanomaterials or a combination of
superparamagnetic iron oxide or gadolinium MR contrast
agents with organic fluorophores or QDs [97, 98]. Data
from FMT have been integrated to radionucleotide meas-
urements obtained by PET [99]. Coregistration of NIRF
signals and CT datasets has been reported based on the
position of fiducial markers detectable by both imaging
devices and software for fusion of 2-D data from FRI with
3-D data obtained from high-resolution flat-panel volume
CT (fpVCT) (Fig. 7)[ 44]. Similar approaches have been
reported for the fusion of FMT data with CT used to
localize high protease activity to the vasculature in an
atherosclerosis mouse model [100]a n dw i t hM R It o
characterize processes of pulmonary inflammation [101].
Furthermore, an approach has been developed to integrate
photoacoustic microscopy and spectral-domain OCT by
simultaneous volumetric microscopic imaging of both
optical absorption and scattering contrasts in biological
tissues [102]. All methods allow successful coregistering of
functional information within the framework of anatomical
structures. Although these approaches are mainly applied
preclinically, as multimodal imaging integrates the strengths
of different modalities to provide comprehensive information
or to assess biological processes in their anatomical context it
Fig. 7 Landmark-based fusion of 2-D NIRF image and 3-D fpVCT
data set. a NIRF image acquired with the Optix MX2 24 h after
application of a Cy5.5 labelled tumour-specific antibody into a mouse
with a subcutaneous tumour (T). Strong fluorescence is detected over
the tumour. Note the fiducial markers (M) that are filled with both
NIRF dye and iodinated contrast agent. b Image fusion of the same
NIRF image and the surface representation of the fpVCT scan
acquired 28 s after intravenous injection of 150 μl Isovist 300 (Bayer
Schering Pharma, Berlin, Germany), shows the exact shape and
location of the tumour. c Image fusion as shown in (b); the fpVCT
scan is depicted as volume-rendering of the skeleton and blood vessels
filled with iodinated contrast agent
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treatment of paediatric disease.
Clinical applications of OI
OI techniques represent easy, inexpensive and harmless
tools to study, diagnose or monitor disease development
and progression. Whereas the role of BLI is restricted to
preclinical examination in animal models, the routine use of
fluorescence-based technologies in the clinic is expanding.
So far, mainly microscopic and micro(endo)scopic techni-
ques are used for diagnostic purposes and during surgical
procedures.
Confocal endomicroscopes have already been applied in
patients, for example to elucidate malignant lesions or
inflammatory processes of the human skin, cervix and oral
cavity, or to endomicroscopically explore the gastric and
colonic mucosae, biliary tract and the proximal and distal
respiratory system [103]. High-resolution imaging by
multiphon tomography is performed in humans for a variety
of skin diseases [104].
Due to the significant improvement in OCT imaging
performance in recent years e.g., the development of
ultrabroad-bandwidth and tunable light sources, hand-
held systems as well as the enhancement of image
contrast and noninvasive depth-resolved functional imag-
ing, OCT has been found more and more its way into
clinical application in paediatric patients [105]. For
example, in paediatric ophthalmology, OCT has already
been used to image the retina in order to diagnose infants
with genetic disorders, e.g., congenital X-linked retino-
schisis [106, 107] and autosomal-recessive neurocutaneous
Sjögren-Larsson syndrome, by studying morphological
changes in the macula of children with a crystalline macular
dystrophy [108]. In neurofibromatosis-2, neurologically
asymptomatic children with a severe phenotype can also be
early diagnosed by detection of epiretinal membranes using
OCT [109]. OCT may also contribute to monitoring juvenile
glaucoma progression [110]. The development of easy-to-
handle hand-held devices, such as a spectral domain OCT,
provides a further possibility to assess pathological changes
of the infant eye [111]. In dermatology, OCT combined with
multiphoton microscopy enables beside the generation of
wide-field images of skin lesions with depth information up
to 2 mm, the generation of high-resolution stacks of
horizontal multiphoton images of the region of interest. This
allows not only early detection of skin cancer, but also
investigation of inflammatory and autoimmune diseases as
well as detection of vascular lesions and deformation in
children [104]. Furthermore, OCT has been shown to be a
h e l p f u ld i a g n o s t i ct o o li nc h i l d r e nw i t hm i l do rm a r k e d
villous atrophy for diagnosing coeliac disease during upper
gastrointestinal endoscopy, avoiding biopsies [112, 113].
Another interesting technique, NIR spectroscopy
(NIRS) that measures the wavelength and intensity of
the absorption of NIR light by intact tissue, is increas-
ingly used as a noninvasive, inexpensive and portable
method to measure blood flow or tissue oxygenation and
thereby to study, for example, functional brain activity in
infants. Since haemoglobin, myoglobin, and cytochrome
c oxidase are the only biological compounds to exhibit
variable absorption of NIR light in response to changes
in oxygen availability, NIRS can determine changes in
tissue oxygen and haemodynamics [114]. For example,
frequency-domain NIRS was shown in a pilot study to be
useful to identify neonates with brain injury by assessing
increased cerebral blood vol u m ea n do x y g e nc o n s u m p t i o n
[115]. Furthermore, combined with diffusion correlation
spectroscopy that provides a measure of tissue perfusion
based on the movement of scatter, frequency-domain
NIRS has been shown to be a safe and quantitative
bedside method to monitor cerebral tissue oxygenation,
cerebral blood volume and cerebral blood flow index in
human premature neonates in the first 6 weeks of life
[116]. Since fluorescence and diffuse reflectance spectros-
copy provide noninvasive methods to assess haemody-
namics and metabolism of the brain they can be used for
delineation of the true resection margin of an epileptic
cortical lesion in epilepsy surgery [117].
In several disciplines of surgical oncology, intraoperative
OI facilitates detection of residual tumour tissue at the
resection edge. For example, time-domain OCT allows
distinction between normal brain, diffusely invaded brain
tissue and solid tumour and thereby the discrimination of
the tumour-to-brain interface [118]. Intraoperative brain OI
of 5-aminolevulinic acid, an optical dye that is metabolized
preferentially by tumour cells, has been shown to allow
precise resections of malignant gliomas [119, 120] and a
benign paediatric brain tumour [121]. Also ICG
fluorescence angiography offers potential for a reliable
intraoperative assessment of paediatric cardiac surgery,
especially when complicated blood vessel reconstructions
and delicate anastomoses are needed [122]. The method
appears safe in children and allows the intraoperative
assessment of vessels and anastomotic patency. The
results are comparable to common procedures such as
echocardiograms and cardiac cineangiograms [122].
In the future, image-guided intraoperative NIRF imaging in
combination with specific molecular probes targeting bio-
markersofpaediatrictumourswillassistthepaediatricsurgeon
and even the pathologist during oncological surgery. Multiple
targeted molecular probes have been already evaluated for
their suitability to intraoperatively assess a variety of tumour
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malignancies, the most common biomarkers in clinical use
are alpha-fetoprotein in liver and yolk sac tumours, chorionic
gonadotropin in germ cell tumours and catecholamines and
neuron-specific enolase in neuroblastoma. Hopefully, with
more studies aimed at the discovery of potential protein
biomarkers for paediatric tumours, novel probes targeting
tumour-associated proteins will emerge in the near future.
Conclusion
InvivoOIwithfluorescenceorbioluminescence assources of
contrast have become powerful tools to unravel mechanisms
underlying diseases (including paediatric disorders), to diag-
nose and design and to evaluate the efficacy of novel
therapeutic concepts. The increasing availability of improved
bioluminescent reporter systems, NIRF dyes and targeted or
activatable fluorescent probes, as well as the development of
multifunctional probes in combination with multimodal
imaging devices and mouse models of paediatric tumours or
genetic disorders will have a significant impact in providing
insights in molecular events of paediatric diseases. Since
fluorescence-based imaging techniques have limited depth
penetration and limited quantification, FRI and FMT are still
mainlyusedexperimentally,althoughtheyhavegrowingroles
in clinical translation especially in analyzing structures close
toanaccessibletissuesurface.Mostpromisingareendoscopic
fluorescence-based technologies that are less hampered by the
low penetration depth offering effective and minimally-
invasive procedures for future application in patients. The
development of appropriate low-cost instrumentation and the
design and clinical approval of novel targeted probes will
further facilitate the translation into the clinic.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Hilderbrand SA, Weissleder R (2010) Near-infrared fluorescence:
application to in vivo molecular imaging. Curr Opin Chem Biol
14:71–79
2. Ntziachristos V, Ripoll J, Wang LV et al (2005) Looking and
listening to light: the evolution of whole-body photonic imaging.
Nat Biotechnol 23:313–320
3. Zacharakis G, Shih H, Ripoll J et al (2006) Normalized
transillumination of fluorescent proteins in small animals. Mol
Imaging 5:153–159
4. Napp J, Dullin C, Muller F et al (2010) Time-domain in vivo
near infrared fluorescence imaging for evaluation of matriptase
as a potential target for the development of novel, inhibitor-based
tumor therapies. Int J Cancer 127:1958–1974
5. McCormack E, Micklem DR, Pindard LE et al (2007) In vivo
optical imaging of acute myeloid leukemia by green fluorescent
protein: time-domain autofluorescence decoupling, fluorophore
quantification, and localization. Mol Imaging 6:193–204
6. MontetX,NzichV,GrimmJetal(2005)Tomographicfluorescence
mapping of tumor targets. Cancer Res 65:6330–6336
7. Ntziachristos V, Schellenberger EA, Ripoll J et al (2004)
Visualization of antitumor treatment by means of fluorescence
molecular tomography with an annexin V-Cy5.5 conjugate. Proc
Natl Acad Sci USA 101:12294–12299
8. Montet X, Figueiredo JL, Alencar H et al (2007) Tomographic
fluorescence imaging of tumor vascular volume in mice.
Radiology 242:751–758
9. Haller J, Hyde D, Deliolanis N et al (2008) Visualization of
pulmonary inflammationusing noninvasive fluorescencemolecular
imaging. J Appl Physiol 104:795–802
10. Tan Y, Jiang H (2008) Diffuse optical tomography guided
quantitative fluorescence molecular tomography. Appl Opt
47:2011–2016
11. Gerger A, Hofmann-Wellenhof R, Sanronigg H et al (2009) In
vivo confocal laser scanning microscopy in the diagnosis of
melanocytic skin tumours. Br J Dermatol 160:475–481
12. Wang BG, Konig K, Halbhuber KJ (2010) Two-photon
microscopy of deep intravital tissues and its merits in clinical
research. J Microsc 238:1–20
13. Drexler W, Fujimoto JG (2008) State-of-the-art retinal optical
coherence tomography. Prog Retin Eye Res 27:45–88
14. Huang D, Swanson EA, Lun CP et al (1991) Optical coherence
tomography. Science 254:1178–1181
15. Wang X, Pang Y, Ku G et al (2003) Noninvasive laser-induced
photoacoustic tomography for structural and functional in vivo
imaging of the brain. Nat Biotechnol 21:803–806
16. Zhang HF, Maslov K, Stoica G et al (2006) Functional
photoacoustic microscopy for high-resolution and noninvasive
in vivo imaging. Nat Biotechnol 24:848–851
17. Morise H, Shimomura O, Johnson FH et al (1974) Intermolecular
energy transfer in the bioluminescent system of Aequorea.
Biochemistry 13:2656–2662
18. Prasher DC, Eckenrode VK, Ward WW et al (1992) Primary
structure of the Aequorea victoria green-fluorescent protein. Gene
111:229–233
19. Hoffman RM (2009) Imaging cancer dynamics in vivo at the
tumor and cellular level with fluorescent proteins. Clin Exp
Metastasis 26:345–355
20. Shaner NC, Steinbach PA, Tsien RY (2005) A guide to choosing
fluorescent proteins. Nat Methods 2:905–909
21. Pauli J, Brehm R, Spieles M et al (2010) Novel fluorophores as
building blocks for optical probes for in vivo near infrared
fluorescence (NIRF) imaging. J Fluoresc 20:681–693
22. Resch-Genger U, Grabolle M, Cavaliere-Jarocot S et al (2008)
Quantum dots versus organic dyes as fluorescent labels. Nat
Methods 5:763–775
23. Weissleder R, Pittet MJ (2008) Imaging in the era of molecular
oncology. Nature 452:580–589
24. Shu X, Royant A, Lin MZ et al (2009) Mammalian expression of
infrared fluorescent proteins engineered from a bacterial phyto-
chrome. Science 324:804–807
25. Shcherbo D, Merzlyak EM, Chepurnykh TV et al (2007) Bright
far-red fluorescent protein for whole-body imaging. Nat Methods
4:741–746
26. Zhou L, El-Deiry WS (2009) Multispectral fluorescence imaging. J
Nucl Med 50:1563–1566
27. Tung CH (2004) Fluorescent peptide probes for in vivo
diagnostic imaging. Biopolymers 76:391–403
172 Pediatr Radiol (2011) 41:161–17528. Kubota K, Kita J, Shimoda M et al (2006) Intraoperative
assessment of reconstructed vessels in living-donor liver trans-
plantation, using a novel fluorescence imaging technique. J
Hepatobiliary Pancreat Surg 13:100–104
29. Dzurinko VL, Gurwood AS, Price JR (2004) Intravenous and
indocyanine green angiography. Optometry 75:743–755
30. Altinoglu EI, Russin TJ, Kaiser JM et al (2008) Near-infrared
emitting fluorophore-doped calcium phosphate nanoparticles for
in vivo imaging of human breast cancer. ACS Nano 2:2075–
2084
31. Park K, Lee S, Kang E et al (2009) New Generation of
Multifunctional Nanoparticles for Cancer Imaging and Therapy.
Adv Funct Mater 19:1553–1566
32. Pirollo KF, Chang EH (2008) Does a targeting ligand influence
nanoparticle tumor localization or uptake? Trends Biotechnol
26:552–558
33. Hamidi M, Azadi A, Rafiei P (2006) Pharmacokinetic consequences
of pegylation. Drug Deliv 13:399–409
34. Choi HS, Liu W, Liu F et al (2010) Design considerations for
tumour-targeted nanoparticles. Nat Nanotechnol 5:42–47
35. Herbort CP, LeHoang P, Guex-Crosier Y (1998) Schematic
interpretation of indocyanine green angiography in posterior
uveitis using a standard angiographic protocol. Ophthalmology
105:432–440
36. BrancatoR,TrabucchiG(1998) Fluoresceinandindocyaninegreen
angiography in vascular chorioretinal diseases. Semin Ophthalmol
13:189–198
37. Raabe A, Beck J, Gerlach R et al (2003) Near-infrared
indocyanine green video angiography: a new method for
intraoperative assessment of vascular flow. Neurosurgery
52:132–139
38. Lewis JD, Destito G, Zijlstra A et al (2006) Viral nanoparticles
as tools for intravital vascular imaging. Nat Med 12:354–360
39. Lee PJ, Peyman GA (2003) Visualization of the retinal and
choroidal microvasculature by fluorescent liposomes. Methods
Enzymol 373:214–233
40. Larson DR, Zipfel WR, Williams RM et al (2003) Water-soluble
quantum dots for multiphoton fluorescence imaging in vivo.
Science 300:1434–1436
41. Scheuer W, Friess T, Burtscher H et al (2009) Strongly enhanced
antitumor activity of trastuzumab and pertuzumab combination
treatment on HER2-positive human xenograft tumor models.
Cancer Res 69:9330–9336
42. Hilger I, Leistner Y, Berndt A et al (2004) Near-infrared
fluorescence imaging of HER-2 protein over-expression in
tumour cells. Eur Radiol 14:1124–1129
43. Ogawa M, Kosaka N, Choyke PL et al (2009) In vivo molecular
imaging of cancer with a quenching near-infrared fluorescent
probe using conjugates of monoclonal antibodies and indocya-
nine green. Cancer Res 69:1268–1272
44. Dullin C, Zientkowska M, Napp J et al (2009) Semiautomatic
landmark-based two-dimensional-three-dimensional image fusion
in living mice: correlation of near-infrared fluorescence imaging of
Cy5.5-labeled antibodies with flat-panel volume computed tomog-
raphy. Mol Imaging 8:2–14
45. Stuhmer W, Alves F, Hartung F et al (2006) Potassium channels
as tumour markers. FEBS Lett 580:2850–2852
46. Holliger P, Hudson PJ (2005) Engineered antibody fragments
and the rise of single domains. Nat Biotechnol 23:1126–1136
47. Matsumura Y, Maeda H (1986) A new concept for macromolecular
therapeutics in cancer-chemotherapy - mechanism of tumoritropic
accumulation of proteins and the antitumor agent smancs. Cancer
Res 46:6387–6392
48. van Osdol W, Fujimori K, Weinstein JN (1991) An analysis of
monoclonal antibody distribution in microscopic tumor nodules:
Consequences of a "binding site barrier." Cancer Res 51:4776
49. Rudnick SI, Adams GP (2009) Affinity and avidity in
antibody-based tumor targeting. Cancer Biother Radiopharm
24:155–161
50. Baxter LT, Jain RK (1989) Transport of fluid and macro-
molecules in tumors. I. Role of interstitial pressure and
convection. Microvasc Res 37:77–104
51. Lee SB, Hassan M, Fisher R et al (2008) Affibody molecules for
in vivo characterization of HER2-positive tumors by near-infrared
imaging. Clin Cancer Res 14:3840–3849
52. Biswal NC, Gamelin JK, Yuan B et al (2010) Fluorescence
imaging of vascular endothelial growth factor in tumors for mice
embedded in a turbid medium. J Biomed Opt 15:016012
53. Chen WT, Mahmood U, Weissleder R et al (2005) Arthritis
imaging using a near-infrared fluorescence folate-targeted probe.
Arthritis Res Ther 7:R310–R317
54. Chen XY, Conti PS, Moats RA (2004) In vivo near-infrared
fluorescence imaging of integrin a, alpha(v)beta(3) in brain
tumor xenografts. Cancer Res 64:8009–8014
55. Veiseh M, Gabikan P, Bahrami SB et al (2007) Tumor paint: A
Chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization
of cancer foci. Cancer Res 67:6882–6888
56. Weissleder R, Tung CH, Mahmood U et al (1999) In vivo
imaging of tumors with protease-activated near-infrared fluores-
cent probes. Nat Biotechnol 17:375–378
57. Tung CH, Mahmood U, Bredow S et al (2000) In vivo imaging
of proteolytic enzyme activity using a novel molecular reporter.
Cancer Res 60:4953–4958
58. Jaffer FA, Kim DE, Quinti L et al (2007) Optical visualization
of cathepsin K activity in atherosclerosis with a novel,
protease-activatable fluorescence sensor. Circulation 115:2292–
2298
59. Messerli SM, Prabhakar S, Tang Y et al (2004) A novel method
for imaging apoptosis using a caspase-1 near-infrared fluorescent
probe. Neoplasia 6:95–105
60. Bremer C, Tung CH, Weissleder R (2001) In vivo molecular
target assessment of matrix metalloproteinase inhibition. Nat
Med 7:743–748
61. Law B, Curino A, Bugge TH et al (2004) Design, synthesis, and
characterization of urokinase plasminogen-activator-sensitive
near-infrared reporter. Chem Biol 11:99–106
62. Kim K, Lee M, Park H et al (2006) Cell-permeable and
biocompatible polymeric nanoparticles for apoptosis imaging. J
Am Chem Soc 128:3490–3491
63. Lee S, Cha E-J, Park K et al (2008) A near-infrared-fluorescence-
quenched gold-nanoparticle imaging probe for in vivo drug
screening and protease activity determination. Angew Chem Int
Ed Engl 47:2804–2807
64. Yang Z, Zheng S, Harrison WJ et al (2007) Long-circulating
near-infrared fluorescence core-cross-linked polymeric micelles:
synthesis, characterization, and dual nuclear/optical imaging.
Biomacromolecules 8:3422–3428
65. Razkin J, Josserand V, Boturyn D, Jin Z, Dumy P, Favrot M,
Coll JL, Texier I (2006) Activatable fluorescent probes for
tumour-targeting imaging in live mice. Chem Med Chem
1:1069–1072
66. Tung CH, Zeng Q, Shah K et al (2004) In vivo imaging of beta-
galactosidase activity using far red fluorescent switch. Cancer Res
64:1579–1583
67. Gong H, Zhang B, Little G et al (2009) beta-Galactosidase
activity assay using far-red-shifted fluorescent substrate
DDAOG. Anal Biochem 386:59–64
68. Zhang GJ, Chen TB, Connolly B et al (2009) In vivo optical
imaging of LacZ expression using lacZ transgenic mice. Assay
Drug Dev Technol 7:391–399
69. Ho NH, Weissleder R, Tung CH (2007) A self-immolative reporter
for beta-galactosidase sensing. Chembiochem 8:560–566
Pediatr Radiol (2011) 41:161–175 17370. Gatenby RA, Gillies RJ (2004) Why do cancers have high
aerobic glycolysis? Nat Rev Cancer 4:891–899
71. Galande AK, Weissleder R, Tung CH (2006) Fluorescence probe
with a pH-sensitive trigger. Bioconjug Chem 17:255–257
72. Povrozin YA, Markova LI, Jatarets AL et al (2009) Near-
infrared, dual-ratiometric fluorescent label for measurement of
pH. Anal Biochem 390:136–140
73. Zhang Z, Achilefu S (2005) Design, synthesis and evaluation of
near-infrared fluorescent pH indicators in a physiologically
relevant range. Chem Commun (Camb) 47:5887–5889
74. StockC,MuellerM,KraehlungHetal(2007)pHnanoenvironment
at the surface of single melanoma cells. Cell Physiol Biochem
20:679–686
75. Urano Y, Asanuma D, Hama Y et al (2009) Selective molecular
imaging of viable cancer cells with pH-activatable fluorescence
probes. Nat Med 15:104–109
76. Li C, Xia J, Wei X et al (2010) pH-activated near-infrared
fluorescence nanoprobe imaging tumors by sensing the acidic
microenvironment. Adv Funct Mater 20:2222–2230
77. Gould SJ, Subramani S (1988) Firefly luciferase as a tool in
molecular and cell biology. Anal Biochem 175:5–13
78. Wood KV, Lam YA, Seliger HH et al (1989) Complementary
DNA coding click beetle luciferases can elicit bioluminescence
of different colors. Science 244:700–702
79. Lorenz WW, McCann RO, Longiaru M et al (1991) Isolation and
expression of a cDNA-encoding Renilla-reniformis luciferase.
Proc Natl Acad Sci USA 88:4438–4442
80. Tannous BA, Kim DE, Fernandez JL et al (2005) Codon-
optimized Gaussia luciferase cDNA for mammalian gene
expression in culture and in vivo. Mol Ther 11:435–443
81. Sjollema J, Sharma PK, Dijkstra RJ et al (2010) The potential for
bio-optical imaging of biomaterial-associated infection in vivo.
Biomaterials 31:1984–1995
82. Luker KE, Luker GD (2008) Applications of bioluminescence
imaging to antiviral research and therapy: multiple luciferase
enzymes and quantitation. Antivir Res 78:179–187
83. Troy T, Jekil-McMullen D, Sambuletti L et al (2004)
Quantitative comparison of the sensitivity of detection of
fluorescent and bioluminescent reporters in animal models.
Mol Imaging 3:9–23
84. Morioka I, Wong RJ, Abate A et al (2006) Systemic effects of
orally-administered zinc and tin (IV) metalloporphyrins on heme
oxygenase expression in mice. Pediatr Res 59:667–672
85. Zhao H, Wong RJ, Nguyen X et al (2006) Expression and
regulation of heme oxygenase isozymes in the developing mouse
cortex. Pediatr Res 60:518–523
86. Vooijs M, Jonkers J, Lyons S et al (2002) Noninvasive imaging
of spontaneous retinoblastoma pathway-dependent tumors in
mice. Cancer Res 62:1862–1867
87. Stubbs MC, Kim YM, Krivtsov AV et al (2008) MLL-AF9
and FLT3 cooperation in acute myelogenous leukemia:
development of a model for rapid therapeutic assessment.
Leukemia 22:66–77
88. Safran M, Kim WY, O’Connell F et al (2006) Mouse model for
noninvasive imaging of HIF prolyl hydroxylase activity: assess-
ment of an oral agent that stimulates erythropoietin production.
Proc Natl Acad Sci USA 103:105–110
89. Xie YC, Yin Y, Wiegraebe Wet al (2009) Detection of functional
haematopoietic stem cell niche using real-time imaging. Nature
457:97–101
90. Carlon M, Toelen J, Van der Perren A et al (2010) Efficient gene
transfer into the mouse lung by fetal intratracheal injection of
rAAV2/6.2. Mol Ther Jul 27 [Epub ahead of print]
91. Sacco A, Doyonnas R, Kraft P et al (2008) Self-renewal and
expansion of single transplanted muscle stem cells. Nature
456:502–506
92. Edinger M, Cao YA, Verneris MR et al (2003) Revealing
lymphoma growth and the efficacy of immune cell therapies
using in vivo bioluminescence imaging. Blood 101:640–648
93. Cheng JC, Kinjo K, Judelson DR et al (2008) CREB is a critical
regulator of normal hematopoiesis and leukemogenesis. Blood
111:1182–1192
94. Kondo A, Goldman S, Vanin EF et al (2009) An experimental
brainstem tumor model using in vivo bioluminescence imaging
in rat. Childs Nerv Syst 25:527–533
95. Miretti S, Roato I, Taulli R et al (2008) A mouse model of
pulmonary metastasis from spontaneous osteosarcoma monitored
in vivo by luciferase imaging. PLoS ONE 3:e1828
96. Rousseau J, Escriou V, Perrot P et al (2010) Advantages of
bioluminescence imaging to follow siRNA or chemotherapeutic
treatments in osteosarcoma preclinical models. Cancer Gene
Ther 17:387–397
97. Bridot JL, Faure AC, Laurent S et al (2007) Hybrid gadolinium
oxide nanoparticles: multimodal contrast agents for in vivo
imaging. J Am Chem Soc 129:5076–5084
98. Jin T, Toshioka Y, Fujii F et al (2008) Gd3+-functionalized near-
infrared quantum dots for in vivo dual modal (fluorescence/magnetic
resonance) imaging. Chem Commun (Camb) 44:5764–5766
99. Nahrendorf M, Keliher E, Marinelli B et al (2010) Hybrid PET-
optical imaging using targeted probes. Proc Natl Acad Sci USA
107:7910–7915
100. Nahrendorf M, Waterman P, Thurber G et al (2009) Hybrid in
vivo FMT-CT imaging of protease activity in atherosclerosis
with customized nanosensors. Arterioscler Thromb Vasc Biol
29:1444–1451
101. Ntziachristos V (2009) Optical imaging of molecular signatures
in pulmonary inflammation. Proc Am Thorac Soc 6:416–418
102. Jiao S, Xie Z, Zhang HF et al (2009) Simultaneous multimodal
imaging with integrated photoacoustic microscopy and optical
coherence tomography. Opt Lett 34:2961–2963
103. Thiberville L, Salaun M, Lochkar S et al (2009) Human in vivo
fluorescence microimaging of the alveolar ducts and sacs during
bronchoscopy. Eur Respir J 33:974–985
104. Konig K, Speicher M, Buckle R et al (2009) Clinical optical
coherence tomography combined with multiphoton tomography
of patients with skin diseases. J Biophotonics 2:389–397
105. Kiernan DF, Mieler WF, Hariprasad SM (2010) Spectral-domain
optical coherence tomography: a comparison of modern high-
resolution retinal imaging systems. Am J Ophthalmol 149:18–31
106. Gerth C, Zawadzki RJ, Heon E et al (2009) High-resolution retinal
imaging in young children using a handheld scanner and Fourier-
domain optical coherence tomography. J AAPOS 13:72–74
107. Dhingra S, Patel CK (2010) Diagnosis and pathogenesis of
congenital X-linked retinoschisis with optical coherence tomography.
J Pediatr Ophthalmol Strabismus 47:105–107
108. Fuijkschot J, Cruysberg JR, Willemsen MA et al (2008)
Subclinical changes in the juvenile crystalline macular dystrophy
in Sjogren-Larsson syndrome detected by optical coherence
tomography. Ophthalmology 115:870–875
109. Sisk RA, Berrocal AM, Schefler AC et al (2010) Epiretinal
membranes indicate a severe phenotype of neurofibromatosis
type 2. Retina 30:S51–58
110. Mrugacz M, Bakunowicz-Lazarczyk A (2005) Optical coherence
tomography measurement of the retinal nerve fiber layer in normal
and juvenile glaucomatous eyes. Ophthalmologica 219:80–85
111. Scott AW, Farsiu S, Enyedi LB et al (2009) Imaging the infant
retina with a hand-held spectral-domain optical coherence
tomography device. Am J Ophthalmol 147(364–373):e2
112. Masci E, Mangiavillano B, Barera G et al (2009) Optical
coherence tomography in pediatric patients: a feasible technique
for diagnosing celiac disease in children with villous atrophy.
Dig Liver Dis 41:639–643
174 Pediatr Radiol (2011) 41:161–175113. Cucchiara S, Di Nardo G (2009) Optical coherence tomography
in children with coeliac disease. Dig Liver Dis 41:630–631
114. Lloyd-Fox S, Blasi A, Elwell CE (2010) Illuminating the
developing brain: the past, present and future of functional near
infrared spectroscopy. Neurosci Biobehav Rev 34:269–284
115. Grant PE, Roche-Labarbe N, Surova N et al (2009) Increased
cerebral blood volume and oxygen consumption in neonatal
brain injury. J Cereb Blood Flow Metab 29:1704–1713
116. Roche-Labarbe N, Carp SA, Surova N et al (2010) Noninvasive
optical measures of CBV, StO2, CBF index, and rCMRO2 in
human premature neonates' brains in the first six weeks of life.
Hum Brain Mapp 31:341–352
117. Bhatia S, Ragheb J, Johnson M et al (2008) The role of optical
spectroscopy in epilepsy surgery in children. Neurosurg Focus
25:E24
118. Bohringer HJ, Lankenau E, Stellmacher F et al (2009) Imaging of
human brain tumor tissue by near-infrared laser coherence
tomography. Acta Neurochir (Wien) 151:507–517, discussion 517
119. Nabavi A, Thurm H, Zountas B et al (2009) Five-aminolevulinic
acid for fluorescence-guided resection of recurrent malignant
gliomas: a phase ii study. Neurosurgery 65:1070–1076, discussion
1076–1077
120. Widhalm G, Wolfsberger S, Minchev G et al (2010) 5-
Aminolevulinic acid is a promising marker for detection of
anaplastic foci in diffusely infiltrating gliomas with nonsignifi-
cant contrast enhancement. Cancer 116:1545–1552
121. Ruge JR, Liu J (2009) Use of 5-aminolevulinic acid for
visualization and resection of a benign pediatric brain tumor. J
Neurosurg Pediatr 4:484–486
122. Kogon B, Fernandez J, Kanter K et al (2009) The role of
intraoperative indocyanine green fluorescence angiography in
pediatric cardiac surgery. Ann Thorac Surg 88:632–636
123. Tanaka E, Choi HS, Fujii H et al (2006) Image-guided
oncologic surgery using invisible light: completed pre-clinical
development for sentinel lymph node mapping. Ann Surg
Oncol 13:1671–1681
Pediatr Radiol (2011) 41:161–175 175